Bone Biologics Corp Stock Debt To Equity
| BBLGW Stock | USD 20.20 0.00 0.00% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
Bone |
Bone Biologics Corp Company Debt To Equity Analysis
Bone Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Bone Biologics Corp has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Bone Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 | ||||
| Number Of Shares Shorted | 197 | ||||
| EBITDA | (4.22 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 377.71 K | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Beta | 0.93 | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 3.48 M | ||||
| Net Asset | 3.86 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.